Excellent
Partially Aligned
Patient Risk:
Low
Summary
Claims are not in conflict with the provided FDA label content for BIKTARVY; however, the supplied label excerpts do not support the approval-year or availability-duration statements, so those elements cannot be verified against the provided prescribing information.
Category Scores
Accurate Statements
Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing FTC and/or TDF, and may occur with discontinuation of BIKTARVY; patients who discontinue BIKTARVY should be closely monitored with both clinical and laboratory follow-up for at least several months and anti-hepatitis B therapy may be warranted.
Supported by FDA labeling section 5.1 (and reiterated in section 17).
Unsupported Statements
Biktarvy was approved by the U.S. Food and Drug Administration in 2018.
The provided FDA-approved prescribing information excerpts do not include approval year or any regulatory timeline.
Biktarvy has been available for about 6–7 years as of 2025–2026.
The provided FDA-approved prescribing information excerpts do not include market availability dates/duration.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only label-supported clinical safety content provided concerns hepatitis B exacerbation risk after discontinuation; the unsupported timeline claims do not create direct clinical safety risk based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Two claims (FDA approval year and duration of availability) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Remove or qualify timeline/availability claims, or cite prescribing information sections that explicitly state approval date/availability; focus on label-supported safety information such as hepatitis B exacerbation after discontinuation.